About Orphazyme ApS
Orphazyme ApS is a publicly listed company based in Copenhagen (Denmark) founded in 2009. Therapeutics for rare genetic diseases are developed by Orphazyme ApS. Orphazyme ApS has raised $59.02 million across 6 funding rounds from investors including Idinvest Partners, Kurma Partners and Kreos Capital. The company has 141 employees. Its chief executive, as recorded, is Anders Fink Vadsholt. Orphazyme ApS offers products and services including Investment Services and Partnership Facilitation. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is ORPHAZYME A/S.
Company details
Orphazyme ApS was founded in 2009 and is headquartered in Copenhagen, Denmark. Operations focus on the biotechnology sector, where innovative therapies are developed for lysosomal storage diseases and other rare genetic disorders. Arimoclomol has been advanced for indications including Niemann-Pick disease Type C, Gaucher disease, amyotrophic lateral sclerosis, and sporadic inclusion body myositis. The company targets unmet needs in genetic disease treatment through clinical-stage programs.
- Headquarters Copenhagen, Denmark
- Employees 141
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website orphazyme.com
- Social X
- Legal Name Orphazyme A/S
- Total Equity Funding$59.02M (USD)
in 6 rounds
- InvestorsIdinvest Partners
& 7 more
- Employee Count141
Products & Services of Orphazyme ApS
Orphazyme ApS offers a comprehensive portfolio of products and services, including Investment Services and Partnership Facilitation.
Provides strategic partnerships and active ownership in growth companies
Facilitates investments in capital shares and properties for returns
Funding Insights of Orphazyme ApS
Orphazyme ApS has successfully raised a total of $59.02M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $59.02M
- Total Rounds 6
- Investors Count 8
All 6 funding rounds of Orphazyme ApS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | Post-IPO | – | – | – | |
| Aug 2019 | $10.01M | Debt – Conventional | – | – | |
| Mar 2017 | $15.02M | Series B | – | Life Sciences Partners, ALS Investment Fund | |
| Jan 2015 | $24M | Series B | – | Kurma Partners | |
| Sep 2011 | $20M | Series A | – | – | |
| Feb 2011 | Seed | – | – |
8 investors in total: 8 institutional.
Investors in Orphazyme ApS
Orphazyme ApS has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Idinvest Partners, Kurma Partners and Kreos Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt is provided to growth-stage companies across multiple sectors. | 1998 | kreoscapital.com | London, United Kingdom | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
A venture capital fund focused on biotech for neurodegeneration. | alsinvestmentfund.com | Amsterdam, Netherlands | ||
Biotech startups are funded through venture capital in life sciences. | 2009 | kurmapartners.com | Paris, France | |
Equity investments are provided to low and middle market companies. | 1997 | idinvest.com | Paris, France | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Investments are made by Sunstone in early-stage European companies. | sunstone.eu | Copenhagen, Denmark | ||
Aescap is focused on investing in high-growth biotech companies. | aescap.com | Amsterdam, Netherlands |
Investor details for Orphazyme ApS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Orphazyme ApS
8 people are tracked at Orphazyme ApS (4 in leadership, 3 in board & advisors, 1 in team); the tracked headcount is 141.
| Name | Role | Group |
|---|---|---|
Anders Fink Vadsholt | CEO | Leadership |
Anders Vadsholt | CEO & CFO | Leadership |
Anders Fink V. | Chief Executive Officer | Leadership |
Christine i Dali | VP Head of Clinical Science | Leadership |
Jakob Bendtsen | Board Member | Board & advisors |
Jakob Have | Board Member | Board & advisors |
Michael Hove | Chairman | Board & advisors |
Raffaella Magnoni | Senior Scientist | Team |
Complete people profiles for Orphazyme ApS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Orphazyme ApS
4 dated milestones of Orphazyme ApS across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Orphazyme ApS is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Web traffic of Orphazyme ApS
Websites that share an audience with Orphazyme ApS (orphazyme.com).
Websites whose visitors overlap most with Orphazyme ApS. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
bmrn.com | bmrn.com | 100% | #5,261,449 | – | |
| adienne.com | 92% | View details | |||
mannosidosis.org | mannosidosis.org | 57% | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Orphazyme Aps
Complete news archive for Orphazyme ApS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orphazyme ApS
Orphazyme ApS was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Orphazyme ApS is headquartered in Copenhagen, Denmark.
Anders Fink Vadsholt is the CEO of Orphazyme ApS, as recorded in our data.
Orphazyme ApS is a funded company, having raised a total of $59.02M across 6 funding rounds to date.
Orphazyme ApS has 141 employees.
Orphazyme ApS was founded in 2009 and is headquartered in Copenhagen, Denmark. Operations focus on the biotechnology sector, where innovative therapies are developed for lysosomal storage diseases and other rare genetic disorders. Arimoclomol has been advanced for indications including Niemann-Pick disease Type C, Gaucher disease, amyotrophic lateral sclerosis, and sporadic inclusion body myositis. The company targets unmet needs in genetic disease treatment through clinical-stage programs.
Orphazyme ApS offers Investment Services and Partnership Facilitation.
Orphazyme ApS has 8 investors. Key investors include Idinvest Partners, Kurma Partners, Kreos Capital, Life Sciences Partners, and ALS Investment Fund.
Orphazyme ApS operates through Orphazyme A/S.